GW Pharmaceuticals is a British biopharmaceutical company known for its multiple sclerosis treatment product nabiximols (brand name, Sativex) which was the first natural cannabis plant derivative to gain market approval in any country. Another cannabis-based product, Epidiolex, for treatment of epilepsy, was approved for treatment of epilepsy in 2018.
Europe risks “slow death” in innovation unless it builds its own Silicon Valley, argues digital health investor Laurent van Lerberghe. With Macron pushing Anglo-French tech sovereignty, the UK and France…
The latest from UK pharma, including teething troubles and industry pushback for the country’s new life sciences strategy; Sanofi snapping up UK vaccines outfit Vicebio for USD 1.6 billion; and…
A roundup of the biggest UK pharma news, including the industry’s uncertain position after the UK-US trade accord; Haleon’s full takeover of its Chinese joint venture; AstraZeneca’s acquisition of Belgian…
UK Prime Minister Keir Starmer’s government continues its push to overhaul the country’s iconic National Health Service (NHS). After originally announcing plans to restructure NHS England, the body that manages…
Japan was once a global leader in life sciences innovation, introducing about a third of the world’s new drugs in the 1980s, but this positioning slipped following decades of economic…
Throughout the year PharmaBoardroom has talked to pharma and biotech executives and life sciences opinion leaders across the globe, gathering vital insights into local markets, learning about promising new therapies,…
A summary of some of the biggest stories coming out of Japan’s pharma industry, including Teva’s divestment of joint venture Teva-Takeda; GE HealthCare’s takeover of Nihon Medi-Physics; Takeda’s blood cancer…
Seen by most as life-sciences friendly, the UK Government’s 2024 Autumn Budget not only pledges to increase funding for the country’s ailing National Health Service (NHS), but to dedicate additional…
A roundup of top stories from UK pharma and healthcare, including the innovative manufacturing fund comprised in the government’s new life-sciences-focused budget; GSK’s autoimmune therapy deal with Chimagen Biosciences; Northern…
AstraZeneca’s Anna Litsiou, Carolyn Hynes and Allison Guy, contributing to the September 2024 edition of DIA’s Global Forum magazine, discuss the importance of improving interactions between health technology assessment (HTA)…
The newly elected UK government’s Secretary of State for Health and Social Care Wes Streeting has a full plate of challenges ahead. Britain’s National Health Service (NHS) is plagued with…
Managing director of Otsuka Pharmaceutical Hong Kong Koji Ueda explains the Japanese company’s long-standing presence in Hong Kong, which dates back to 1956, the affiliate’s 50-50 split between pharmaceuticals and…
See our Cookie Privacy Policy Here
